人脐带血干细胞治疗骨关节炎的研究进展  

Research progress of human umbilical cord blood stem cells in the treatment of osteoarthritis

作　　者：田思嫚 牛映祯 马隽[2] 董江涛[1] TIAN Si-man;NIU Yingzhen;MA Jun;DONG Jiang-tao(Department of Orthopedic Surgery,The Third Hospital,Hebei Medical University,Shijiazhuang,Hebei 050051,China;Stem Cell Laboratory,Hebei Medical University,Shijiazhuang,Hebei 050051,China)

机构地区：[1]河北医科大学第三医院关节外科,河北石家庄050051 [2]河北医科大学干细胞实验室,河北石家庄050051

出　　处：《中国矫形外科杂志》2025年第1期58-63,共6页Orthopedic Journal of China

基　　金：国家自然科学基金委员会面上项目(编号:H2020206562);河北省科学技术厅援疆科技计划项目(编号:V164483028949);河北医科大学“十四五”临床医学创新研究团队支持计划项目(编号:2022LCTD-B25)。

摘　　要：骨关节炎(osteoarthritis,OA)是一种以软骨损伤为特征的慢性退行性关节疾病,严重影响患者生活质量,而临床上现有的治疗方法均不能阻断OA的进展。间充质干细胞(mesenchymal stem cell,MSCs)及其外泌体因其再生软骨的能力,在治疗OA中展现出广阔的应用前景。其中人脐带血来源的间充质干细胞(human umbilical cord blood-derived mesenchymal stem cells,hUCB-MSCs)具有无创采集法、高增殖性、低免疫原性等优势,被认为是一种更有效的细胞来源治疗OA。hUCB-MSCs分泌的外泌体作为细胞间信使,可通过其携带的生物活性因子治疗OA。本文综述了hUCB-MSCs及其外泌体在OA治疗中的应用进展,为OA治疗提供新的思路。Osteoarthritis(OA)is a chronic degenerative joint disease characterized by cartilage damage,which seriously affects thequality of life of patients,and none of the available clinical treatments can halt the progression of OA.Mesenchymal stem cells(MSCs)andtheir exosomes show promising applications in the treatment of OA due to their ability to regenerate cartilage.Among them,human umbilicalcord blood-derived mesenchymal stem cells(hUCB-MSCs)have the advantages of non-invasive collection method,high proliferation,andlow immunogenicity,which is considered to be a more effective cell source for the treatment of OA.Exosomes secreted by hUCB-MSCs(huc-MSCs-EXOs)act as intercellular messengers that can treat OA through the bioactive factors they carry.In this paper,we reviewed the prog-ress of hUCB-MSCs and their exosomes in OA treatment to provide new ideas for OA treatment.

关 键 词：骨关节炎 人脐带血间充质干细胞 外泌体 软骨再生 免疫调节 

分 类 号：R684.3[医药卫生—骨科学]